Pulmonary arterial hypertension (PAH) is a disease with no known cure 1 , characterized by obstructive vascular lesions of the distal pulmonary arteries (PA) due in part to excessive proliferation 2, 3 and resistance to apoptosis 4, 5 of the pulmonary artery smooth muscle cells (PASMC). This phenotype is often associated with a chronic inflammatory response characterized by sustained elevation of circulating pro-inflammatory molecules such as TNF and IL-6 6 . Although an environment of strong inflammation is known to be toxic for the cells and is known to induce DNA damage [7] [8] [9] , PAH-PASMC apparently adapt to these unfavorable environmental conditions and are able to survive and proliferate. Indeed, PAH-PASMC share several features with cancer cells (which also proliferate under unfavorable conditions of accumulated genetic damage or hypoxia), including the expression of pro-survival proteins such
as Pim-1 10 and survivin 11 and a metabolic switch toward glycolysis even under normoxia (known as the Warburg effect 12 ). We have recently shown that all of these changes can be sustained in time by the downregulation of the microRNA miR-204 13 , and the subsequent activation of the transcription factors NFAT and HIF-1 14 .
Nonetheless, a question remains unanswered: How can PAH-PASMC adapt to the DNA damage caused by sustained inflammation? We hypothesized that PAH is associated with a sustained activation of the DNA repair machinery that, in addition to DNA repair, may also directly promote PASMC proliferation.
Poly(ADP-ribose) polymerase-1 (PARP-1) is the best characterized and most abundant member of the PARP family, which currently comprises 6 members 15 . Upon activation, by binding to DNA double-strand breaks (DSB), PARP-1 uses Nicotinamide adenine dinucleotide (NAD + ) to generate large amounts of poly(ADP-ribose) (pADPr) along the break-site and therewith contributes actively to DNA repair [16] [17] [18] . PARP-1 can trigger DNA repair and therewith accumulated genetic damage or hypoxia), including the expression of pro-surviv val a al p p pro o ote te ein in ins s s su su s c ch as Pim-1 10 and survivin 11 and a metabolic switch toward glycolysis even under normoxia (known as s t t the he he W W War ar arbu bu bur rg e e eff ff ffec e t 12 ). We have recently show w wn n n t th hat all of thes se e e chan an ng ge ges can be sustained in i i ime e me by the do own wn nr re egu gula lati ti tion on on o o of f f th the e e m mi mic cr ro o oRN NA A miR R R--204 4 4 13 3 3 , a a and d d th th he su subs bs b eq eq que uent nt nt a act ctiv iv ivat at atio io i n n of of of t t the he he r ran an nsc sc cri ri r pt pt p io io on n n fa fact ct tor r rs s N NF NFAT AT A a a and nd nd H H HIF IF IF-1 -1 1 14 4 . . allow/promote cell survival (when limited stress leads to a light to moderate PARP-1 activation)
or promote cell death when the stress and the subsequent PARP-1 activation and hence its NAD + consumption are excessive. PARP-1 can function as a cellular stress sensor 19 . In addition to DNA repair, PARP-1 may be implicated in many other features seen in PAH. For example, PARP-1 is implicated in the transcriptional regulation of a number of genes involved in PAH including IL-6 20 . Cells with activated PARP-1 produce high levels of IL-6, which can amplify inflammation and, by activating STAT3 21 , can contribute to NFAT and HIF-1 activation which promotes the apoptosis resistance that characterizes PAH-PASMC. Using lung tissues and primary cultures of distal pulmonary artery PASMC from both humans and rodents, we demonstrate for the first time that PAH is associated with sustained DNA damage that leads to PARP-1 activation. PARP-1 activation promotes cell survival and proliferation by triggering a miR-204-dependent activation of NFATc2 and HIF-1 . Most importantly, we show that the clinically available PARP inhibitor ABT-888 reverses the PAH in vivo in two PAH rat models.
Methods

All experiments were performed with Laval University and the IUCPQ Biosafety and Ethics
Committee. The online-only Data Supplement provides more details on all methods, including the supplies and chemicals used.
Human tissue samples
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by guest on April 13, 2017 http://circ.ahajournals.org/ Downloaded from followed by a Tukey-Kramer post-test was used for more than two groups. When same cells were used under different conditions, paired analyses were performed among treatments.
Furthermore, if variance depends on mean of the data, statistical analyses were performed on log transformation of the data. Probability values less than 0.001 (***), 0.01 (**), and 0.05 (*) were considered as statistically significant.
Results
Increased DNA damage and PARP-1 expression in human PAH
We measured DNA damage in human distal pulmonary arteries (PA) from 6 PAH and 6 control patients (5 distal PA/patient), using the expression of the p53-binding protein 1 (53BP1) measured by immunohistochemistry, as marker of DNA damage 22 . As shown in Figure 1a , DNA damage is significantly increased in PAH compared to normal tissue controls. Cells with positive nuclear staining were considered positive and this was divided by the total amount of cells (total nuclei) to calculate percent of positive cells. Immunohistochemisty negative control is provided in Supplemental Figure 1a . We then measured PARP-1 protein expression in human distal PA from 5 control and 5 PAH patients by immunoblot (Figure 1b ) and found that PARP-1 expression is significantly increased in PAH compared to control distal PAs. Thus, we studied whether these changes were also present in primary cultured human PAH-PASMC. PAH-PASMC were freshly isolated from small PA of 4 PAH patients and 5 control PASMC cell lines were purchased. DNA damage and PARP-1 expression and activation were measured. Using -H2AX as DNA damage marker, we showed that, as in distal PAs, DNA damage is sustained in cultured PAH-PASMC compared to healthy PASMC. The number of -H2AX foci in PAH-PASMC are further increased by the addition of the PARP-1 inhibitor ABT-888 or AG14361 as patients (5 distal PA/patient), using the expression of the p53-binding protein 1 (5 (5 53B 3B BP1 P1 P1) ) ) measured by immunohistochemistry, as marker of DNA damage 22 . As shown in Figure 1a , DNA da am ma mage ge ge i i is s s si si sig g gnif f fic ic ica an antly increased in PAH compa a are r r d d d to normal tis ssu su s e co co on nt ntrols. Cells with positive d n nuc cl lea e r staining ng w wer ere e co co ons ns sid id ider er ered ed p p po os osit tiv ive an n nd d this s s w w was s d d div ivi id de ed ed b b by th the e t t tot ta al l am am amou oun n nt o o of f f c ce cell ll lls s (t (t ( o ot otal nu nucl cl c ei ei ei) ) ) to to c c cal al alcu cula la ate e e p pe er erc ce ent nt o o of f f po po posi si siti ti tive ve c cel el ells ls ls. . Imm mm mmun un noh oh his s sto to toc ch chem em emi is sty ty y n n neg eg ega at ativ ive e e co co ont ntro ro rol l l is s pr ro rovi vi ide e ed d n Suppleme ent nt n al al a F F Fig ig igur ur ure e 1a 1a 1a. . We We We t t the he en n me me meas as asur ur ured ed ed P P PAR AR ARP-P-1 1 1 pr pr prot ot o ei ei ein n n ex x xpr pr pres es essi si sion on on in n n hu hu huma ma man n distal PA by guest on April 13, 2017 http://circ.ahajournals.org/ Downloaded from well as with PARP-siRNA (compared to siSCRM treated cells) (Figure 1c) suggesting that PARP-1 activation is important for the repair of these damages but not enough to eliminate them completely as a certain level of DNA damage persists in PAH-PASMC. This suggests that PARP-1 activation in PAH is mild, far from the level of activation that can be reached afterradiation for example 19 . By western blot, we then demonstrated that PAH-PASMC have increased levels of PARP-1 and the further you increase DNA damage (by blocking the repair by ABT-888) the further PARP-1 expression is increased (Figure 1d) . The same effect is also seen with AG14361 treatments (Supplemental Figure 1b) . Moreover, as expected, although PARP-1 siRNA increases DNA damage, it did not increase PARP-1 expression demonstrating siRNA efficiency (Supplemental Figure 1b) . Note that although ABT-888 increases PARP-1 expression it inhibits its activity 23 assayed using the chemiluminescent PARP assay kit ( Figure   1e ). We also confirmed that AG14361 blocks PARP-1 activity using the same assay (Figure 1e ).
To evaluate DNA repair, we measured fold changes in DNA damage after DNAdamaging agent etoposide 24 treatment and a 2 hours recovery. Fold change were analyzed since PAH-PASMC have higher basal levels of DNA damage (Figure 1c) . In brief, cells were treated with 1mM of etoposide for 1 h and after withdrawal of etoposide, cells were incubated in fresh medium for 2 hours to allow DNA repair, as previously described 25 . The reminding DNA damage was then assessed (g-H2AX). For ABT-888 treatments, cells were incubated with 10mM
ABT-888 for 48 hours prior to etoposide treatment and ABT-888 was kept in medium for the recovery period. As shown in Figure 2a , control PASMC treated with etoposide have increased DNA damage (3.5 fold increase). On the other hand, in PAH-PASMC, etoposide doesn't significantly increase DNA damage, suggesting that increased PARP-1 expression in these cells provides a more efficient DNA repair in the 2-hour recovery period. Indeed, if PARP activity is efficiency (Supplemental Figure 1b) . Note that although ABT-888 increases PA PA ARP RP RP--1 1 expression it inhibits its activity 23 assayed using the chemiluminescent PARP assay kit (Figure   1e e). ). ). W W We e e al al also so s c con n nfi fi fir rm rmed that AG14361 blocks PA AR ARP P-1 activity usi si ing n t the he he s same assay (Figure 1e) To eva alu lua at a e e e DN DN DNA A A re re repa pa pai ir ir, , we we we m mea ea asure e ed d d fol ld d c cha a an ng nges es s i in n n D DN DNA A da da dam ma mage ge ge a a aft fter er r D D DNA NA NA--da dama ma magi gi ging ng g a a age ge g nt nt e eto to opo po osi side de d 24 t t tre reat at atme me ment nt a and nd nd a a a 2 2 h h hou ou urs rs s re e ecov ov ove er ery. y. y. 
PARP inhibition decreases proliferation and promotes apoptosis in PAH-PASMC
We next studied the implication of PARP-1 in PAH-PASMC survival and proliferation. We showed that PAH-PASMC have significantly greater proliferation rate (PCNA, Ki67 and WST1
The mechanism accounting for increased DNA damage and PARP-1 pro ote te ein in n exp xp xpre re ress ss ssi io ion n i ikely to be multi-factorial, but the presence of sustained inflammatory signaling in PAH may f pl lay ay ay a a a m m maj aj ajor or o r rol le. e. e H H Hence, we measured whether r TN TN TNF-, an inflamm mm m at tor or ory y y cytokine increased and m mp pl plic i ated in PA PA AH H H pa path thog og ogen en enes es esis is 26 6 26 , , , c ca can n n t tr rigg g ger r r DN N NA A A da a am ma mag g ge a and nd d s sub ubse se equ u uen en nt t t P PA PARP RP RP-1 -1 -1 a a act ct ti iv iva at atio o on n n P P PAS AS ASMC MC C. . As A As s sho ho own wn n in n n Fi F gu gu gure re e 2 2 2b b b, , co co ont nt ntro ro rol l l PA PA PASM SM MC C tr trea ea eate te ted wi wi w t th th T T TNF NF NF-h ha ad ad a a an n in in inc c crea ea ase e ed d 
PAH-PASMC
We have previously described a critical role of the microRNA miR-204 in the etiology of PAH 13 .
We had demonstrated that through a STAT3-dependent mechanism the downregulation of miR-204 accounts for the upregulation of the transcription factors NFAT and HIF-1 in PAH-PASMC, which is contributing to their proliferation and resistance to apoptosis 5, 27 . Cells with activated PARP-1 produce high levels of IL-6 28 , which by activating STAT3 21 contributes to miR-204 downregulation. We previously published that PAH-PASMC produce higher levels of IL-6 and have activated STAT3 14 . Thus, by regulating IL-6 production, PARP-1 will downregulate miR- do down wn wnre re regu gu gula la ati ti tion on. . W W We e p pr prev ev e io iou us usly ly y p p pub ub ubli lis sh shed ed ed t t tha ha at t t P PAH AH AH-P P PAS AS ASMC MC MC p pr ro rodu du duce ce e h h hig ig i he he her r le le l ve ve vels ls ls o of f f IL IL L-6 -6 an nd nd t t t have activated ed d S S STA TA TAT3 T3 T3 14 14 14 . Th Th Thus us u , by by by r r reg eg e ul ul ulat at tin in ing g g IL IL IL-6 -6 6 p p pro ro r du du uct ct ctio io ion, n, n, P P PAR AR ARP-P-P-1 1 wi wi w ll ll ll d dow ow ownr nr nreg eg egul u ate miR- PA PASM SM SMC C C (n (n (n=3 = =3, , p< p< p<0 0. 0.00 00 001) 1) 1). . We We a a als ls l o o o o ob obse se er r rve ve ved d d th th hat at at t t the he he A A ABT BT BT-8 -8 -888 88 88 e eff ff fec ec ect t t is is s s s sim im imil ilar ar ar t t to o o th th thos ose e e wi wi with th th t t the he he other treatm men en ents ts ts. Mo Mo More re reov ov o er er r, a ad a di di ding ng n A A ABT BT BT-8 -8 888 88 88 to to o o oth th ther e er t tre e reat atme me ment nt nt d doe oe oesn sn n't 't 't c c cha ha hang ng ge e [C [C Ca a a lungs. Furthermore, NFkB lung protein expression and H&E staining shows increased inflammation in PAH models and this seems to be decreased upon ABT-888 treatment (Supplemental Figure 4b) . In order to test whether PARP-1 inhibition can reverse PAH in our established rat models, ABT-888 was given orally (6mg/kg/day) once PAH was established (5 weeks post Sugen injection or 14 days after MCT injection). We confirmed that ABT-888 administration per os decreases PARP-1 activity in the lungs, using the modified PARP-1 activity assay (Supplemental Figure 2b) . We performed a 2-week longitudinal study to assess the efficacy of our treatment using non-invasive hemodynamic assessment with Doppler echocardiography 5 . We observed PARP inhibition in both Sugen-PAH and MCT-PAH rats These findings were invasively confirmed by right heart catheterization (direct PA pressure) and RV/LVS (right ventricle/left ventricle with septum) weight ratio (Figure 5b) . Also, ABT-888 significantly improved exercise capacity in both models, using standard treadmill exercise protocol, compatible with the improvement of the hemodynamic measurements (Supplemental Figure 5a) . Furthermore, no kidney or liver toxicity was seen after ABT-888 treatment in both models, assessed by plasma creatinine and aspartate aminotransferase (AST) levels (Supplemental Figure 5b) .
To determine whether ABT-888 reduced PA remodeling in Sugen-PAH and MCT-PAH animals, we measured medial wall thickness using H&E staining. We observed that animals treated with ABT-888 displayed a significant reduction in medial thickness of distal PAs ( 100 m) (Figure 5c ). As in vitro, these findings were associated with a significant decrease in ignificantly y y im im impr pr prov ov oved ed d e e exe e erc rc rcis is i e e ca ca capa pa paci city ty ty i i in n n bo bo bot th h h mo mo m de de d ls ls s, , , us us usin in ing g g st st stan n nda da dard rd rd t t tre re read ad a mi mi mill ll ll e e exe xe xercise PASMC proliferation (as assessed by Ki67) (Figure 6a ) and resistance to apoptosis (TUNEL) (Figure 6b ).
Finally, ABT-888 provides a therapeutic effect similar to the combination of both standard PAH therapies (Bosentan+Tadalafil) in MCT-PAH rats, while ABT888 given in addition to Bosentan and Tadalafil, provided a greater therapeutic effects compare to MCT-PAH rats treated with Bosentan+Tadalafil only. These findings suggest that ABT-888 could be used in human in combination with current therapies and would provide a more efficient treatment (Supplemental Figure 6 ).
Discussion
Using PAH lungs from both humans and rats we show for the first time that DNA damage may be etiologically implicated in PAH. Clinically, DNA damage has been suspected to be responsible for the occurrence of pulmonary hypertension in patients taking etoposide, an anticancer drug promoting DNA damage and PARP-1 activation 34 . We showed that sustained DNA . PARP-1 inhibition using the clinically available inhibitor ABT-888, reverses all these abnormalities in vitro (Figure 3 and 4) and reverses PAH in vivo in two widely used models of PAH ( Figure 5 and Supplemental Figure 5 and 6). Schematic representation of our signaling pathway is presented in Figure 7 .
Although not previously reported, the presence of increased DNA damage in distal PAs
Using PAH lungs from both humans and rats we show for the first time that DNA NA A d d dam am mag ag age e e ma ma m y y be etiologically implicated in PAH. Clinically, DNA damage has been suspected to be e esp sp pon on onsi si sibl bl ble e e fo fo for th th he e e o occurrence of pulmonary hype pe pert tension in pati ien en e ts t tak ak aki ing etoposide, an anti- in PAH when compared to control patients is not surprising. PAH is characterized by sustained sterile inflammation and elevated circulating cytokines such as TNF and IL-6 6 , both of which are known to promote DNA damage 7, 8 . We demonstrated that exposure of normal PASMC to pro-PAH factors, such as TNF-, IL-6 or PDGF induces DNA damage (Figure 2a and Supplemental Figure 1c) . Similar observations have been described in the systemic circulation within atherosclerotic lesions 35 . Although not explored in the present study, other environmental stresses could also contribute to the increased level of DNA damage in PAH. For example, elevated levels of circulating S100A4, which is upregulated in PAH 36 and is responsible for the advanced glycation end products receptor RAGE activation 37 , is implicated in both DNA damage 38 and PAH 37 . It is possible that PARP-1 activation is a common denominator for diverse conditions that cause DNA damage in PAH, making it an attractive therapeutic target. Although our findings support the implication of DNA damage in PARP activation in PAH, inflammation itself may further contributes to PARP-1 activation (Figure 7 ).
PARP-1 may act as a sensor of intracellular stress 19 . In the presence of extensive DNA damage (as seen after treatment with high doses with gamma radiation for example), PARP-1 is highly activated and promotes cell death, while in the presence of low to moderate DNA damage, as perhaps seen in PAH, PARP-1 triggers DNA repair by recruiting important repair factors to the DNA damage sites 22 , allowing PASMC to survive and even proliferate 19 .
Interestingly, recent studies have demonstrated that a mild to moderate PARP-1 activation can induce pro-proliferative responses by promoting the activation of NFAT 39 , a transcription factor critical for PAH-PASMC proliferation 5 . We previously reported that NFAT activation in PAH occurs downstream of the downregulation of miR-204 and the subsequent activation of STAT3 40, 41 and Pim-1 10, 13, 42 . In the present study, we report that PARP-1 inhibition is associated with a damage 38 and PAH 37 . It is possible that PARP-1 activation is a common denomin in nat at tor o o f f for r or d d div iv iver erse conditions that cause DNA damage in PAH, making it an attractive therapeutic target. Although ou ur r r fi fi find nd ndin in ings gs gs s s sup ppo po port rt the implication of DNA da am ma m g g ge in PARP ac cti ti t vati ti ion on on in PAH, inflammation t tse el lf lf may furth th he er r c c con ont tr t ib ib but t ute es s s t to to P PAR AR ARP P P-1 1 1 act t tiv v vatio on on (Fi i ig gu gure re e 7 7 7). )
PA PARP RP RP-1 -1 m m may ay a a a act t t a as s a a se sens ns nsor or or o of f f in n ntr tr trac ac acel el llu lu l la la ar r st s r re ress ss ss r r 19 19 . . In In n t th he he p p pre re r s s sen nc nce e of of of e ext xt ten en nsiv ve ve D DNA NA NA damage (as s see ee een n n af af afte te ter r tr tr trea e tm tm tmen e e t t t wi wi w th th th h hig ig igh h h do do dose se ses s s wi wi with th h g gam am amma ma ma r r rad ad adia iati ti tion on on f f for or or e e exa xa amp mp mple le le), ), ), P PARP-1 is 33 .
In addition to proliferation, resistance to apoptosis is another important feature of PAH- Recent studies have established a direct link between PARP-1 and the transcription factor HIF-1 in cancer models 46 . In fact, studies have presented PARP1 as a transcriptional co-activator of HIF-1 46 . Upon hypoxic induction of cells, PARP-1 was shown to interact with HIF1-and to regulate the transcriptional activity of HIF-1 -dependent genes. In the present study we showed that PARP-1 inhibition significantly decreases HIF-1 activity resulting in a significant induction of apoptosis. We recently showed that the normoxic upregulation of HIF-1 in PAH-PASMC is attributed to Endoplasmic reticulum (ER) stress disrupting ER mitochondria units, impairing mitochondrial ROS production resulting in HIF-1a activation 47 . Recently in neurons, PARP-1 activation has been shown to promote ER stress. This could explain why PARP-1 inhibition in PAH-PASMC decreases HIF-1a (Figure 4c ) activation and restores mitochondria membrane PAH 33 .
In addition to proliferation, resistance to apoptosis is another impor a tant feature of PAH-PA ASM SM SMC C C 4, 4, 4, 5 5 5 . . . Se S S ve ve era ra ral l reports have demonstrated th th that at abnormal me eta ta taboli li ic/ c/ c/m mi m tochondrial function t pl lay y y a key role e in in in t t thi is s ph ph hen en nom om men enon on on, , , no no ota a ably y b by y pr r ro om mot ot tin in ng g a a a n no norm rm mo ox oxic ic ac c ctiv iv vat at ati io ion n of of of H H HI IF I -1 -1 -1 31, 31, 3 3 33 .
Re Rece ce c nt nt nt s stu tudi di die es es h hav av ve e es esta a abl blis i h he hed d d a a a di di dire rec c ct l l lin in ink k k be be betw tw wee e en n PA PA PARP RP RP-1 -1 1 a and nd nd t t the he h tra ra ans nscr cr c ip ip ipti tion on on fac ac cto o or r H H HIF F-F-1 in cancer m m mod od o el el els s s 46 46 46 . . In In I f f fac ac act, t, t s s stu tu tudi di ies e e h h hav av ave e e pr pr pres es sen en ente te ted d d PA PA ARP RP RP1 1 1 as as as a a t t tra ra rans ns nscr cr crip ip ipti ti t on on ona a al l l co co co-a -activator of f f suggesting that its inhibition may reduce the inflammatory response seen in PAH (as suggested in Supplemental Figure 4b ) and thus improve vascular remodeling. This possibility will be addressed in future studies. Given the diversity of signaling mechanisms and protein expression between proximal and distal PAs, a limitation in our study is the use of human PASMC isolated from somewhat larger distal PAs (1000 m in diameter), as opposed to the less than 300-500μm vessels that are considered to be the typical resistance vessels. However, we managed to confirm our findings using immunofluorescence and immunohistochemistry measurements made in distal pulmonary arteries ( 100 m in diameter). In addition, there is emerging evidence that the proximal PAs may also be involved in PAH pathology, exhibiting remodeling that results in vascular stiffness, in contrast to earlier views suggesting that the primary signal for the disease is of other pathways cannot be ruled out. In fact, the potential role of PARP-1 as a s s str res e e s s se se sens ns nsor or o i in PASMC directly implies the involvement of multiple pathways as many signals may converge to PA ARP RP RP-1 1 -1 a a and nd nd p pro odu du duce c several downstream signal al ls, s, s w w which may vary ry ry acc cc cor or ordi d ng to experimental co on nd nditions or di di is sea a ase e s stat at ates es es. . Fo Fo For r ex ex xa am ampl ple e, PA A AR R RP-1 1 a act tiv iv ivat atio io on n n ca can n p pr prom om mo ot te e c cy cyt to toki ki in ne ne p pro ro odu du duct ct tio io i n n n 48 u ugg gg gges es esti ting ng ng t t tha ha h t t i it ts in inh hi ibi bi iti tion on m m may ay ay r r red ed e u uc uce e e th th the e e in in nfl fl f am am amma ma ato o ory ry ry r res es espo po pons ns se e e se se een n n i in n PA PA PAH H (a (a (as s su sug gg gges es ste ed d n Suppleme ent nt n al al a F F Fig ig igur ur ure e 4b 4b 4b) ) ) an n nd d d th th hus u u i i imp mp mpro ro rove ve ve v v vas as ascu cu cula lar r r re re remo mo mode de deli li l ng ng g. Th Th This is is p p pos os ssi si sibi bi bili li ity ty ty will be restricted within the resistance PAs. Also, the inflammatory environment in PAH, which is increasingly being appreciated, implies that the more proximal PAs are equally exposed to circulating cytokines compared to the more distal arteries.
We focused our study on PASMC and not endothelial cells, which are also implicated in PAH. Although most investigators agree that PA endothelial cell apoptosis is one of the earliest events in the pathogenesis of PAH in which DNA damage might be implicated, less is known about endothelial cell biology as the disease progresses; many suspect that there is a switch Althou ugh gh gh P P PAR AR RP-P--1 1 1 in in inhi hi hib bi biti tion on on a app pp ppears s s t to o be e e e e effe ec ect ti tive ve e i in n n te te erm m ms s of of of r rev eve er ers si sing ng e e est st stab ab blish sh shed d attenuates D DNA NA NA d d dam am amag ag age e e re e epa pa pair i t t thr hr hrou ou ough gh h s sup up uppr pr pres es essi si ing ng ng t t the he e e exp xp xpre re r ss ss ssio io ion n of of of at at atax ax axia ia ia t tel el e an an angi gi giec ec e tasia mu muta tate ted d in in c col olor orec ecta tal l ca canc ncer er PL PLoS oS O One ne 20 2013 13;8 ;8:e :e57 5703 036 6 Values are means ± SEM. IPAH: idiopathic pulmonary arterial hypertension; HPAH: heritable pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; CO: cardiac output; CI: cardiac index; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; 6MWD: six-minute walk distance; PDE5: phosphodiesterase-5. APAH include patients with connective tissue disease and pulmonary veno-occlusive disease associated pulmonary arterial hypertension. Please note than some patients take more than one type of medication. Va Valu lu lues es a a are re re m m mea ea eans ns ± ± SE EM EM. . . PAH AH: : id idi iopa path t ic c p pulmo mona nary art rteria ial l hy hype p rtension on; ; HP HPAH AH: : heri ita tabl ble e pu pulm lmon o ar ry y ar arte teri r al h hyp yper erte tens n io i n; n; A APA AH: H: sso i ciat d ed p l ulmo mona nary ry y a art rter eria ial l hy hy ype pe p rt r en nsi sion on; ; ; CO CO O: ca card rdia iac c ou outp tp put ut; ; CI CI: : ca card rdia iac c i ind ndex ex x; mP mPAP AP: : me mean an p p pul ulmo monary arteri ial l l pr p essure; ; PVR: R: p pul ul lmo mona nary ry v vas ascu ul la lar re esi sist stan ance ce; ; 6 6M 6MWD WD WD: : i si six x-mi minu nute te w wal alk k k di di dist sta ance ce; ; PD PD PDE5 E5 E5: : ph phos osph phod d odie ie i s sterase-5.
associated with increased DNA damage measured by H2AX nuclear staining. As shown, PAH-PASMC have increased DNA damage, which is significantly increased by PARP-1 inhibition (by ABT-888, AG14361 or siPARP-1) (n=4). d) Consequently, PAH-PASMC have increased PARP-1 expression and this is further increased with ABT-888 treatment as demonstrated by western blot (n=4). e) Although PARP-1 expression is increased after ABT-888 treatment, we confirmed that it does block PARP-1 activity (measured by chemiluminescence assay) (n=3).
*p<0.05; **p<0.01 and ***p<0.001 showed that ABT-888 treatment increases apoptosis levels in distal PAs of both animal models.
Only smooth muscle actin positive cells were considered in the calculation of positive cells.
These experiments were performed in 5 distal PAs/rat in 5 rats per group. *p<0.05; **p<0.01 and ***p<0.001. Abcam, 1:500) and HIF-1α (Novus Biological, 1:1000) were quantified and normalized to amidoblack as previously described 4 . All immunoblots were performed in triplicate.
PARP activity assay
PARP activity was assayed using the Trevigen Universal chemiluminescent PARP assay kit according to the manufacturer's instruction, with modifications. Cell lysate (40µg/well) was added to the wells containing PARP buffer and PARP cocktail. Activated DNA and PARP enzyme were not added to cell lysate, as previously described 5 .
Proliferation and apoptosis measurements
To study the effect of PARP-1 on PASMC proliferation and apoptosis in vitro, cultured human PAH-PASMC were exposed to 10% FBS (a condition that is known to promote proliferation 1, 4 ) or 0.1% FBS (a starvation condition that promotes apoptosis 1, 4 ). PASMC proliferation was measured using Ki67 antibody (Millipore) and PCNA (Dako) and apoptosis by using Apoptag apoptosis detection kit (TUNEL; Millipore) and AnnexinV (Clontech). Percent of positive PASMC (Ki67, TUNEL) were determined and divided by the total amount of cells, calculated with DAPI (total nuclei). WST1 assay, also to assess proliferation, was used according to the manufacturer's instruction with modifications. Briefly, 2000 cells/well were plated onto 24-well plates. After stabilization, cells were treated for 48 hours under different conditions. The reagent was added to the medium and after 2h incubation; the absorbance at 440 nm was measured using a microplate reader (Synergy H1, BioTek). Fluo-3AM (Invitrogen) and TMRM (Tetramethylrodamine methyl ester perchlorate, Invitrogen) were measured in PASMC treated with different activators and inhibitors to evaluate the effect of modulating our studied pathway on intracellular calcium and mitochondrial membrane potential (n=20 to 50 cells/experiment in 3 experiments).
DNA damage
Immunofluorescence for γ-H2AX and immunohistochemistry for 53BP1 were performed as previously reported in Rodrigue et al. 6 using a monoclonal antibody directed against γ-H2AX
(Cell Signaling Canada) and a polyclonal antibody against 53BP1 (Bethyl Canada).
Confocal Microscopy/Immunofluorescence
Sections of lungs and human PASMC were used for immunfluorescence staining. PASMC were fixed with 1% paraformaldehyde and permeabilized with 0.2% Triton X-100. 
Animal models
Male Sprague-Dawley rats (250-350g) (strain 400, Charles River) were randomly distributed between the groups and all the hemodynamic measurements were performed blinded to the condition. For the Sugen-hypoxia model (Sugen), rats were injected with 20mg/kg in of SU5416
(Sigma) and put in hypoxia (10% O 2 ) for 3 weeks. Chambers were opened twice a week for cleaning and replenishment of food and water. Oxygen concentrations were continuously monitored with blood gas analyzers. For the monocrotaline-induced PAH model (MCT), rats were injected s.c. with 60 mg/kg of crotaline (Sigma). PAH progression was monitored every week by non-invasive echocardiography measuring the pulmonary artery acceleration times (PAAT) and the right ventricular (RV) hypertrophy. At the end of the treatment period, all rats underwent right heart catheterizations (closed chest) using SciScence catheters to measure pulmonary arterial pressure, as previously described 4, 7 . Histology measurements were performed as previously described 3, 8 . Pulmonary artery wall thickness was measured using 2 measurements/artery in 10 arteries/animal, in at least 5 animals per group. We also performed experiments on MCT-induced PAH in rats to evaluate the therapeutic potential of ABT-888 (6mg/kg/day) compared to actual treatments used in PAH (Bosentan (100mg/kg/day) and Tadalafil (10mg/kg/day)) 9 and all these treatments started 2 weeks after MCT injection (when PAH was established) and were diluted in water to be administered per os. Drinking water was used in all conditions as the vehicle group. 
